COVID-۱۹ Screening in Rheumatologic Diseases Cases; Special Look at Chloroquine Derivate Use

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 203

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_HPR-6-4_003

تاریخ نمایه سازی: 6 تیر 1402

Abstract:

Background: Among suggested medications for the treatment of COVID-۱۹, chloroquine derivates and angiotensin-converting–enzyme inhibitors (ACEIs)/angiotensin II type ۱ receptor blockers (ARBs) are the two medications with conflicting effects on the development of the disease.Objectives: The present study aimed to evaluate COVID-۱۹ in patients with rheumatic diseases receiving chloroquine derivate.Methods: Every patient with proven rheumatologic diseases registered in two referral centers in Tehran and Alborz, Iran was enrolled in the present descriptive cross-sectional study between May and June ۲۰۲۰. At first, the symptoms of COVID-۱۹ were assessed, and if a case had suspicious symptoms, reverse transcription-polymerase chain reaction (RT-PCR) COVID-۱۹ tests were done. Demographic and clinical data are documented for every patient. Then, the patients were grouped once according to their COVID-۱۹ infection status and another time according to their hydroxychloroquine use.Results: ۱۱۵۹ patients enrolled in the study with a mean age of ۴۹.۳۹ years. Frequency of hypertension was ۲۲.۱۷ %, diabetics (۹.۴۹%) and ۲۰ (۱.۷%) patients were positive for COVID-۱۹ testing. The most common symptoms of the COVID-۱۹ positive cases were cough (۵.۲%) and fever (۴%). There was no significant difference in receiving ACEIs/ARBs or other medications between COVID-۱۹ positive or negative patients. Among the patients receiving hydroxychloroquine, ۱۵ patients (۱.۷%) had proved COVID-۱۹ versus ۵ patients (۱.۷%) who were not receiving these medications (P>۰.۹۹۹).Conclusion: The present study demonstrated that receiving ARBs or ACEIs was not different among patients with or without COVID-۱۹. Moreover, receiving chloroquine derivate was not related to the development of COVID-۱۹ in patients with rheumatologic disorders.

Keywords:

Authors

Soraya Shadmanfar

Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Gholamhosein Alishiri

Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Noushin Bayat

Exercise Physiology Research Center, Life Style Institute, Baqyiatallah University of Medical Sciences, Tehran, Iran

Morteza Izadi

Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Ahmad Salimzadeh

Sina Hospital, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abdolrahman Rostamian

Department of Rheumatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Shahla Abolghasemi

Department of Rheumatology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

Mohammad Hossein Azimzadeh Ardebili

Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran

Zeynab Rastgar Moqaddam

Iran University of Medical Science, Tehran, Iran

Marjan Hasani

Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran

Ehsan Rahmanian

Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran

Helia Iranpanah

Shahid Beheshti University of Medical Sciences, Tehran, Iran

Ghodrat Allah Islami

Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran

Amin Saburi

Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran